8-KShareholder Matters

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Shareholder Vote Results (Jun 4, 2010)

Filed June 4, 2010For Securities:ALNY

Summary

This 8-K filing reports on the outcomes of Alnylam Pharmaceuticals, Inc.'s (ALNY) 2010 Annual Meeting of Stockholders held on June 2, 2010. The primary focus for investors is the re-election of two Class III directors, Victor J. Dzau, M.D. and Kevin P. Starr, both of whom were overwhelmingly approved by shareholders and will serve until 2013. Additionally, the company's stockholders approved an amendment to the 2004 Employee Stock Purchase Plan, indicating continued support for employee equity incentives. The filing also confirms the ratification of PricewaterhouseCoopers LLP as the independent auditor for the fiscal year ending December 31, 2010. This procedural approval is standard for public companies and provides assurance regarding financial oversight. Overall, the meeting results indicate strong shareholder confidence in the company's leadership and governance practices.

Key Highlights

  • 1Two Class III directors, Victor J. Dzau, M.D. and Kevin P. Starr, were re-elected to serve until the 2013 annual meeting of stockholders.
  • 2Shareholder approval was granted for an amendment to the Company’s 2004 Employee Stock Purchase Plan.
  • 3PricewaterhouseCoopers LLP was ratified as the independent auditor for the fiscal year ending December 31, 2010.
  • 4The Annual Meeting was held on June 2, 2010, with 41,894,605 shares issued and outstanding as of the record date.
  • 5Director terms of office for John K. Clarke, John M. Maraganore, Ph.D., Vicki L. Sato, Ph.D., Paul R. Schimmel, Ph.D., Phillip A. Sharp, Ph.D., and James L. Vincent continued after the meeting.

Frequently Asked Questions

The main outcomes were the re-election of two Class III directors (Victor J. Dzau, M.D. and Kevin P. Starr), the approval of an amendment to the 2004 Employee Stock Purchase Plan, and the ratification of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2010.

The shareholder vote was overwhelmingly in favor of re-electing Victor J. Dzau, M.D. and Kevin P. Starr, with a substantial majority of votes cast 'For' and minimal 'Votes Withheld' or 'Broker Non-Votes'.

Ratifying the independent auditor, in this case PricewaterhouseCoopers LLP, confirms shareholder approval for their appointment to examine the company's financial statements for the upcoming fiscal year, ensuring independent oversight and compliance.

While two directors were re-elected, the terms of other directors including John K. Clarke, John M. Maraganore, Ph.D., Vicki L. Sato, Ph.D., Paul R. Schimmel, Ph.D., Phillip A. Sharp, Ph.D., and James L. Vincent continued after the Annual Meeting.